By: Adam Feuerstein | 04/10/14 - 11:52 AM EDTLook behind you MannKind (MNKD), here comes another developer of inhaled insulin.
Dance Biopharm filed for $75 million initial public offering on Wednesday night, seeking new money from investors to further develop its own device to deliver insulin to diabetics through their lungs.
I know you're probably wondering, does the world need a second inhaled insulin device, particularly with so many question marks still hovering over MannKind's Afrezza? The answer will depend, partly, on whether or not Dance Biopharm can convince investors to buy into its IPO. Investors haven't exactly warmed to MannKind, even with last week's positive recommendation from the FDA advisory panel. But there are some key differences between Dance Biopharm and MannKind which may make the former more compelling.
This is a photo of Dance Biopharm's device, called Dance 501:
08/26/14 - 07:00 AM EDT
08/25/14 - 08:48 AM EDT
08/21/14 - 10:23 AM EDT
08/14/14 - 10:20 AM EDT
08/13/14 - 12:04 PM EDT
08/29/14 - 12:03 PM EDT
08/28/14 - 12:00 PM EDT
08/27/14 - 11:32 AM EDT
08/26/14 - 14:30 PM EDT
08/26/14 - 11:34 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.